このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Biohit Oyj 将来の成長

Future 基準チェック /26

Biohit Oyjは、12.1%と13.1%でそれぞれ年率12.1%で利益と収益が成長すると予測される一方、EPSはgrowで10.9%年率。

主要情報

14.5%

収益成長率

13.4%

EPS成長率

Medical Equipment 収益成長	26.9%
収益成長率	13.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	08 Aug 2024

今後の成長に関する最新情報

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 17

Recent updates

Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Feb 22

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 17

業績と収益の成長予測

HLSE:BIOBV - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	20	2	2	3	1
12/31/2025	17	2	2	3	1
12/31/2024	15	2	2	3	1
6/30/2024	14	2	-1	0	N/A
3/31/2024	14	2	0	0	N/A
12/31/2023	13	2	1	1	N/A
9/30/2023	12	1	0	1	N/A
6/30/2023	11	1	0	0	N/A
3/31/2023	11	1	1	1	N/A
12/31/2022	11	1	2	2	N/A
9/30/2022	11	1	1	1	N/A
6/30/2022	11	1	1	1	N/A
3/31/2022	10	0	0	0	N/A
12/31/2021	9	-1	0	0	N/A
9/30/2021	9	-2	0	0	N/A
6/30/2021	8	-2	0	0	N/A
3/31/2021	8	-3	0	0	N/A
12/31/2020	7	-3	0	0	N/A
9/30/2020	8	-3	0	0	N/A
6/30/2020	8	-3	0	0	N/A
3/31/2020	9	-2	0	0	N/A
12/31/2019	10	-1	0	0	N/A
9/30/2019	10	-2	0	0	N/A
6/30/2019	10	-2	0	0	N/A
3/31/2019	10	-2	0	0	N/A
12/31/2018	10	-2	0	0	N/A
9/30/2018	10	-2	0	0	N/A
6/30/2018	10	-2	0	0	N/A
3/31/2018	9	2	N/A	-1	N/A
12/31/2017	9	6	N/A	-1	N/A
9/30/2017	9	6	N/A	-1	N/A
6/30/2017	8	6	N/A	-2	N/A
3/31/2017	8	1	N/A	-2	N/A
12/31/2016	8	-3	N/A	-2	N/A
9/30/2016	7	-4	N/A	-3	N/A
6/30/2016	6	-4	N/A	-3	N/A
3/31/2016	7	-3	N/A	-3	N/A
12/31/2015	6	-3	N/A	-3	N/A
9/30/2015	6	-3	N/A	-2	N/A
6/30/2015	6	-4	N/A	-3	N/A
3/31/2015	5	-4	N/A	-4	N/A
12/31/2014	4	-4	N/A	-3	N/A
9/30/2014	4	-5	N/A	-4	N/A
6/30/2014	4	-5	N/A	-4	N/A
3/31/2014	4	-6	N/A	-4	N/A
12/31/2013	3	-6	N/A	-4	N/A
9/30/2013	3	-5	N/A	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BIOBVの予測収益成長率 (年間8.9% ) は貯蓄率 ( 1% ) を上回っています。

収益対市場: BIOBVの収益 ( 8.9% ) Finnish市場 ( 14.8% ) よりも低い成長が予測されています。

高成長収益: BIOBVの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: BIOBVの収益 ( 12.9% ) Finnish市場 ( 3.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: BIOBVの収益 ( 12.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BIOBVの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Biohit Oyj 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 17% to €2.70

Consensus EPS estimates increase by 18%

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Biohit Revises Earnings Guidance for 2023

Biohit Oyj Provides Earnings Guidance for the Year 2023

Biohit Oyj Revises Earnings Guidance for the Year 2022

Recent updates

First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 17% to €2.70

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Consensus EPS estimates increase by 18%

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: Revenues exceed analyst expectations

Biohit Oyj to Report First Half, 2024 Results on Aug 07, 2024

Biohit Oyj Announces Changes in the Management Group

New major risk - Earnings quality

First half 2023 earnings: EPS and revenues exceed analyst expectations

Biohit Revises Earnings Guidance for 2023

Biohit Oyj Approves Election of Vesa Silaskivi as Members of Board of Directors

Full year 2022 earnings released: EPS: €0.04 (vs €0.10 loss in FY 2021)

Investor sentiment deteriorates as stock falls 19%

Biohit Oyj Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Biohit Oyj Announces Executive Changes

Biohit Oyj to Report Fiscal Year 2022 Final Results on Mar 22, 2023

No independent directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biohit Oyj Appoints Jussi Sorvo as Chief Financial Officer, Effective on September 7, 2022

Biohit Oyj Announces Executive Changes

Biohit Oyj Appoints Panu Hendolin as Member of the Management Team

First half 2022 earnings released: EPS: €0.06 (vs €0.073 loss in 1H 2021)

Biohit Oyj Revises Earnings Guidance for the Year 2022

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Biohit Oyj Appoints Lea Paloheimo as the Chairman of the Board of Directors

Biohit Oyj Elects Kalle Härkönen as Board of Director

Less than half of directors are independent

Full year 2021 earnings: Revenues in line with analyst expectations

Biohit Oyj Provides Earnings Guidance for the Year 2022

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Biohit Oyj Specifies Financial Guidance for 2021

Biohit Oyj Announces Recent Clinical Validation Study Confirms the Accuracy of the New-Generation GastroPanel Test in Diagnosis of Atrophic Gastritis and Helicobacter Pylori Infection

First half 2021 earnings released: €0.073 loss per share (vs €0.15 loss in 1H 2020)

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

President & CEO Semi Korpela has left the company

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Full year 2020 earnings released: €0.22 loss per share (vs €0.094 loss in FY 2019)

Full year 2020 earnings released: €0.22 loss per share (vs €0.094 loss in FY 2019)

We Think Biohit Oyj (HEL:BIOBV) Can Afford To Drive Business Growth

New 90-day high: €2.26

Biohit Oyj to Report First Half, 2021 Results on Aug 11, 2021

Biohit Oyj to Report Fiscal Year 2020 Results on Feb 17, 2021

New 90-day low: €1.99

New 90-day low: €2.00

Biohit Oyj Elects Osmo Suovaniemi as the Chairman of the Board of Directors

New 90-day low - €2.14

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘